Novartis AG ADR (NVS)vsOncology Institute Inc (TOI)
NVS
Novartis AG ADR
$157.54
-1.83%
HEALTHCARE · Cap: $288.85B
TOI
Oncology Institute Inc
$5.13
+5.56%
HEALTHCARE · Cap: $512.91M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 10288% more annual revenue ($56.69B vs $545.76M). NVS leads profitability with a 22.5% profit margin vs -8.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.8%
Fair Value
$93.10
Current Price
$157.54
$64.44 premium
Margin of Safety
+22.9%
Fair Value
$3.40
Current Price
$5.13
$1.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 41.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -652.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while TOI is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
TOI is growing revenue faster at 41.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 45/100), backed by strong 22.5% margins. TOI offers better value entry with a 22.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling investment opportunity within the dynamic healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?